Characteristics | Values |
---|---|
Age at bleeding presentation, yrs | |
Mean ± SD | 47 ± 11 |
Median (IQR) | 47 (39–57) |
Range, yrs | 27–68 |
Male | 15/28 (53.5) |
History of EGPA or of any typical symptom of EGPA | |
Pre-bleeding | 24/26 (92.3) |
Post-bleeding | 1/26 (3.8) |
During bleeding | 1/26 (3.8) |
Time EGPA, bleeding*, mos | |
Mean ± SD | 66 ± 60 |
Median (IQR) | 72 (13–102) |
Range | 0–240 |
Site of hemorrhage† | |
Subarachnoid | 14/28 (50.0) |
Intracerebral | 13/28 (46.4) |
Spinal | 3/28 (10.7) |
Intraventricular | 5/28 (17.9) |
Multiple location | 8/28 (28.6) |
Ischemic events coexistence | 3/28 (10.7) |
Clinical manifestations† | |
Asthma | 24/26 (92.3) |
Rhinitis/sinusopathy | 21/24 (87.5) |
Neuropathy | 19/25 (76.0) |
Pulmonary infiltrates | 13/24 (54.2) |
Hypertension | 8/20 (40.0) |
Inflammatory markers | 17/17 (100) |
Eosinophilia | 23/24 (95.8) |
ANCA | |
pANCA and/or MPO specificity | 18/23 (78.3) |
Angiography/computerized tomography angiogram | |
Normal | 7/17 (41.2) |
Vasculitis | 8/17 (47.1) |
Aneurysm/dissection | 4/17 (23.5) |
Death | 4/26 (15.4) |
Poor evolution during the hospitalization | 2/4 |
Recurrence of bleeding 4 years after first event | 1/4 |
Recurrence complicated with infective ventriculitis | 1/4 |
↵* Elapsed time between onset of EGPA (diagnosis or first typical manifestation) and the hemorrhage occurrence.
↵† Cumulated frequencies. EGPA: eosinophilic granulomatosis with polyangiitis; CNS: central nervous system; IQR: interquartile range; ANCA: antineutrophil cytoplasmic antibodies; pANCA: peripheral ANCA; MPO: myeloperoxidase.